Salbutamol in Congenital Myasthenic Syndrome: A Systematic Review
Abstract Background Congenital myasthenic syndromes (CMS) are inherited disorders of neuromuscular transmission with few effective treatments. Salbutamol, a β2-adrenergic agonist, has shown anecdotal benefit, yet no comprehensive assessment of its clinical effectiveness across genetic subtypes exist...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-12-01
|
| Col·lecció: | BMC Neurology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12883-025-04569-8 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|